Patents Assigned to UCB Biopharma SPRL
  • Publication number: 20220162311
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: December 9, 2021
    Publication date: May 26, 2022
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Patent number: 11331438
    Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a first cap body part in the form of a sleeve having forward and rear openings; a second cap body part in the form of a plug arranged for receipt by said forward opening of said sleeve form first cap body part, wherein said plug form second body part defines a plug top and an inner plug body, and wherein said inner plug body defines a protruding pocket; and arranged for receipt within said protruding pocket of the inner plug body, a metal connector defining plural needle cover gripping elements arranged around a central hub, wherein each gripping element is provided with one or more barbs for gripping the needle cover. The first cap body part, second cap body part and connector are provided as separate parts.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: May 17, 2022
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Barry Alan Knight, Marko Frederik Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
  • Patent number: 11324896
    Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a cap body defining an inner and outer cap body; provided to the inner cap body, a grip for gripping the needle cover of said syringe; provided to the outer cap body, an opposing pair of recessed portions, wherein each recessed portion defines a recess base, and wherein each recessed portion is bounded by a peripheral lip; and provided to the recess base of each recessed portion, an over-coating. The cap body comprises a generally rigid material and each over-coating comprises a more flexible material. Each peripheral lip defines banks that extend beyond the over-coating of the recess base.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: May 10, 2022
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Barry Alan Knight, Marko Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
  • Patent number: 11220547
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: January 11, 2022
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • Publication number: 20210371547
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: January 19, 2021
    Publication date: December 2, 2021
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Simon Peter TICKLE, Heather Margaret LADYMAN
  • Patent number: 11059820
    Abstract: Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBK? isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 13, 2021
    Assignee: UCB Biopharma SPRL
    Inventors: Luc Lambert Jozef Jan Aerts, Georges Assaf, Nicolas Edmond Carly, Vincent Adolphe Carol Cool, Jean-Pierre Delatinne, Laurent Jacques Willy Delhaye, Jean Paul Kestemont, Sarah Le Meur
  • Patent number: 10889640
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 12, 2021
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • Publication number: 20200377578
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon MacKenzie, Matthew Cox
  • Patent number: 10829565
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: 10828366
    Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Razwan Hanif, Christopher John Le Page
  • Publication number: 20200291013
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Application
    Filed: January 23, 2018
    Publication date: September 17, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Adrian HALL, Malcolm MACCOSS
  • Patent number: 10774152
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Publication number: 20200277366
    Abstract: The invention relates to multi-specific antibody molecules having specificity for TNF alpha, IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Ralph ADAMS, Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Taul HUMPHERYS, Diane MARSHALL, Stevan Graham SHAW, Daniel John LIGHTWOOD
  • Patent number: 10759844
    Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: September 1, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventor: David Paul Humphreys
  • Patent number: 10752676
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: August 25, 2020
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenzie, Matthew Cox
  • Patent number: 10730952
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Publication number: 20200188607
    Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a first cap body part in the form of a sleeve having forward and rear openings; a second cap body part in the form of a plug arranged for receipt by said forward opening of said sleeve form first cap body part, wherein said plug form second body part defines a plug top and an inner plug body, and wherein said inner plug body defines a protruding pocket; and arranged for receipt within said protruding pocket of the inner plug body, a metal connector defining plural needle cover gripping elements arranged around a central hub, wherein each gripping element is provided with one or more barbs for gripping the needle cover. The first cap body part, second cap body part and connector are provided as separate parts.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 18, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Barry Alan KNIGHT, Marko Frederik PLEVNIK, Norihiko INOUE, Jamie BUCKLEY, Lisa HORNSEY
  • Patent number: 10639423
    Abstract: Provided is a drive unit for an auto-injector having a drive unit housing arranged for docking receipt of a syringe or of a cassette unit comprising a syringe movable from a rest position, in which a needle tip of the syringe is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture; and a drive arrangement including one or more electrically powered sources of axial drive; a first drive transfer element for advancing the syringe to said use position; and a second drive transfer element for moving a plunger into the barrel of the syringe to eject liquid contents thereof. The drive unit housing is provided with a skin sensor arrangement having an array of plural skin sensor electrodes located about the needle delivery aperture.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: May 5, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Martin John McLoughlin, Michael James David Heald, Cameron Townley Charles, Dylan Sanders Garrett, Kevin Richard Lozeau
  • Patent number: 10639424
    Abstract: Provided is a drive unit for an auto-injector having a drive unit housing arranged for docking receipt of a syringe or of a cassette unit comprising a syringe movable from a rest position, in which a needle tip of the syringe is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture; and a drive arrangement including one or more electrically powered sources of axial drive; a first drive transfer element for advancing the syringe to said use position; and a second drive transfer element for moving a plunger into the barrel of the syringe to eject liquid contents thereof. The drive unit housing is provided with a skin sensor arrangement having an array of plural skin sensor electrodes located about the needle delivery aperture.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 5, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Martin John Mcloughlin, Michael James David Heald, Cameron Townley Charles, Dylan Sanders Garrett, Kevin Richard Lozeau
  • Patent number: 10626143
    Abstract: The present invention provides a novel method for manufacturing a protein, particularly where said protein is to be coupled with another molecule. The invention further provides a method for industrial scale protein manufacturing to obtain proteins, e.g., for therapeutic purposes.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 21, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Christopher Mark Illidge, Neil Alan Watson